MorphoSys grants Dana-Farber Institute rights to its Slonomics technology to develop immunity against viral infections

MorphoSys AG

Germany / Mid-Cap Biopharma ($1-$50 billion)

Licensor

This is a sample profile. To view the full content of this profile and many others, log in to BCIQ or sign up for a free trial today!

Dana-Farber Cancer Institute

U.S. / Academic

Licensee

This is a sample profile. To view the full content of this profile and many others, log in to BCIQ or sign up for a free trial today!

Active

Sample

01/01/2009

announced